Epigenetic Dysregulation of Myeloproliferative Neoplasms

Secondary leukemia to myeloproliferative neoplasms

(2020) Andrew Dunbar et al.   BLOOD

PRMT5 inhibition modulates E2F1 methylation and gene regulatory networks leading to therapeutic efficacy in JAK2V617F mutant MPN

(2020) Friederike Pastore et al.   Cancer Discovery

Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses

(2020) Vibe Skov   Cancers

Splicing Anomalies in Myeloproliferative Neoplasms: Paving the Way for New Therapeutic Venues

(2020) Marie Hautin et al.   Cancers

Impact of high molecular risk mutations on transplant outcomes in patients with myelofibrosis

(2019) Roni Tamari et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Epigenomic profiling of myelofibrosis reveals widespread DNA methylation changes in enhancer elements and ZFP36L1 as a potential tumor suppressor gene epigenetically regulated

(2019) Nicolás Martínez-Calle et al.   HAEMATOLOGICA

ASXL1 alteration cooperates with JAK2V617F to accelerate myelofibrosis

(2019) Ying Guo et al.   LEUKEMIA

A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis

(2019) Prithviraj Bose et al.   LEUKEMIA & LYMPHOMA

Unravelling Intratumoral Heterogeneity through High-Sensitivity Single-Cell Mutational Analysis and Parallel RNA Sequencing

(2019) Alba Rodriguez-Meira et al.   MOLECULAR CELL

Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis

(2019) Jong Jin Jeong et al.   Cancer Discovery

HDAC11 Deficiency or Inhibition Disrupts Oncogene-Induced Stress Hematopoiesis in Myeloproliferative Neoplasms

(2019) Lanzhu Yue et al.   BLOOD

The identification of fibrosis-driving myofibroblast precursors reveals new therapeutic avenues in myelofibrosis

(2018) Rafael Kramann et al.   BLOOD

Single cell approaches identify the molecular network driving malignant hematopoietic stem cell self-renewal

(2018) Mairi S. Shepherd et al.   BLOOD

Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms

(2018) Maria Kleppe et al.   CANCER CELL

Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies

(2018) Robert L. Bowman et al.   Cell Stem Cell

The role of IDH mutations in acute myeloid leukemia

(2018) Guillermo Montalban-Bravo et al.   Future Oncology

JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition

(2018) Anna Sophia McKenney et al.   JOURNAL OF CLINICAL INVESTIGATION

Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation

(2018) Reina Nagase et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Modeling ASXL1 mutation revealed impaired hematopoiesis caused by derepression of p16Ink4a through aberrant PRC1-mediated histone modification

(2018) Masahiro Uni et al.   LEUKEMIA

A phase II study of ruxolitinib in combination with azacytidine in patients with myelofibrosis

(2018) Lucia Masarova et al.   BLOOD

Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation

(2018) Sebastien Jacquelin et al.   BLOOD

Classification and Personalized Prognosis in Myeloproliferative Neoplasms

(2018) Jacob Grinfeld et al.   NEW ENGLAND JOURNAL OF MEDICINE

The distinct biological implications of Asxl1 mutation and its roles in leukemogenesis revealed by a knock-in mouse model

(2017) Yueh-Chwen Hsu et al.   Journal of Hematology & Oncology

BET Proteins as Targets for Anticancer Treatment

(2017) Anastasios Stathis et al.   Cancer Discovery

Epigenetic changes in myelofibrosis: Distinct methylation changes in the myeloid compartments and in cases with ASXL1 mutations

(2017) Helene Myrtue Nielsen et al.   Scientific Reports

DNA Hypomethylating Drugs in Cancer Therapy

(2017) Takahiro Sato et al.   Cold Spring Harbor Perspectives in Medicine

Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm

(2016) Yue Yang et al.   BLOOD

Loss ofEzh2synergizes withJAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis

(2016) Takafumi Shimizu et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition

(2016) Goro Sashida et al.   JOURNAL OF EXPERIMENTAL MEDICINE

BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells

(2016) D T Saenz et al.   LEUKEMIA

Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib

(2015) K. P. Patel et al.   BLOOD

Effect of Mutation Order on Myeloproliferative Neoplasms

(2015) Christina A. Ortmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms

(2014) E. Chen et al.   BLOOD

Lysine-specific demethylase 1 (LSD1) in hematopoietic and lymphoid neoplasms

(2014) D. Niebel et al.   BLOOD

Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator

(2014) T. Kameda et al.   BLOOD

Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms

(2014) P. Lundberg et al.   BLOOD

The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients

(2014) P Guglielmelli et al.   LEUKEMIA

Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

(2014) Katrina J. Falkenberg et al.   NATURE REVIEWS DRUG DISCOVERY

Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes

(2014) Siddhartha Jaiswal et al.   NEW ENGLAND JOURNAL OF MEDICINE

A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF)

(2013) John Mascarenhas et al.   BRITISH JOURNAL OF HAEMATOLOGY

JAK1/2 and Pan-Deacetylase Inhibitor Combination Therapy Yields Improved Efficacy in Preclinical Mouse Models of JAK2V617F-Driven Disease

(2013) E. Evrot et al.   CLINICAL CANCER RESEARCH

Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms

(2013) C. Perez et al.   HAEMATOLOGICA

Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo

(2013) Omar Abdel-Wahab et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Mutations and prognosis in primary myelofibrosis

(2013) A M Vannucchi et al.   LEUKEMIA

Efficacy of vorinostat in a murine model of polycythemia vera

(2012) H. Akada et al.   BLOOD

ASXL1 Mutations Promote Myeloid Transformation through Loss of PRC2-Mediated Gene Repression

(2012) Omar Abdel-Wahab et al.   CANCER CELL

Methylome Profiling Reveals Distinct Alterations in Phenotypic and Mutational Subgroups of Myeloproliferative Neoplasms

(2012) S. Nischal et al.   CANCER RESEARCH

Mutation analysis ofASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12,andTET2in myeloproliferative neoplasms

(2012) Mandy Brecqueville et al.   GENES CHROMOSOMES & CANCER

Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation

(2012) A Sprüssel et al.   LEUKEMIA

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK2V617F-Mediated Phosphorylation of PRMT5 Downregulates Its Methyltransferase Activity and Promotes Myeloproliferation

(2011) Fan Liu et al.   CANCER CELL

IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F

(2011) A Tefferi et al.   LEUKEMIA

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis

(2010) A Tefferi et al.   LEUKEMIA

IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms

(2010) A Pardanani et al.   LEUKEMIA

Somatic Mutations ofIDH1andIDH2in the Leukemic Transformation of Myeloproliferative Neoplasms

(2010) Anthony Green et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells

(2009) Y. Wang et al.   BLOOD

JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin

(2009) Mark A. Dawson et al.   NATURE

A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis

(2008) A Quintás-Cardama et al.   LEUKEMIA